Theratechnologies Inc. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET
Company Participants
Elif McDonald - Senior Director, Investor Relations
Paul Levesque - President & CEO
Philippe Dubuc - SVP & CFO
Christian Marsolais - SVP & Chief Medical Officer
John Mullaly - IR, LifeSci Advisors
Conference Call Participants
Edward Nash - Canaccord Genuity
Andre Uddin - Research Capital
Endri Leno - National Bank
Operator
Good morning and welcome to the Theratechnologies' Second Quarter Fiscal Year 2022 Earnings Call. [Operator Instructions]. Please note, this event is being recorded.
I'd now like to turn the conference over to Elif McDonald, Senior Director of Investor Relations. Please go ahead.
Elif McDonald
Thank you, Andrea. Good morning, everyone. My name is Elif McDonald and I recently joined Theratechnologies to lead the Investor Relations program. I am thrilled to be here and look forward to working closely with the amazing team at Theratechnologies, our investors, analysts and capital market partners. I am especially excited about working with their outstanding management team and our exceptional board of directors.
On the call today, you'll be hearing from our President and Chief Executive Officer, Mr. Paul Levesque and Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc. In addition, we'll be joined by Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer and Mr. John Leasure, our Global Commercial Officer for our Q&A session.
Before we begin, I'd like to remind everyone that Theratechnologies' remarks today contains forward-looking statements regarding its current and future plan, expectations and intentions, results, levels of activity, performance, goals or achievements, or other future events or developments. In preparing these forward-looking statements, several assumptions were made by Theratechnologies, and there are risks that results obtained by the company will differ materially from those statements. As such, the company cannot guarantee that any forward-looking statement will materialize, and you are cautioned not to place undue reliance on them. Theratechnologies refers current and potential investors to the forward-looking information section of its management discussion and analysis filings issued this morning as available on Sedar at www.sedar.com and on EDGAR at sec.gov. Forward-looking statements represent Theratechnologies' expectations as of July 13, 2022. Except as may be required by securities law, Theratechnologies does not undertake any obligation to update any forward-looking statement whether as a result of new information, future events or otherwise.
With that, I would now like to turn the conference call over to Theratechnologies' President and CEO, Mr. Paul Levesque.